Quantitative perfusion scintigraphy (QPS) or the anatomic segment method (ASM) for estimating postoperative pulmonary function (PF) in patients treated for non-small cel lung cancer (NSCLC): a retrospective comparison

T. Holvoet, J. van Meerbeeck, E. Derom (Ghent, Belgium)

Source: Annual Congress 2009 - Respiratory mechanics, tissue and cell dysfunction in pulmonary disease

Session: Respiratory mechanics, tissue and cell dysfunction in pulmonary disease
Session type: E-Communication Session
Number: 1730

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
T. Holvoet, J. van Meerbeeck, E. Derom (Ghent, Belgium). Quantitative perfusion scintigraphy (QPS) or the anatomic segment method (ASM) for estimating postoperative pulmonary function (PF) in patients treated for non-small cel lung cancer (NSCLC): a retrospective comparison. Eur Respir J 2009; 34: Suppl. 53, 1730

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Use of Bode index (BI) in patients with COPD undergoing inpatient pulmonary rehabilitation (IPR) after lung resection (LR) for non small cell lung cancer (NSCLC) Source: Eur Respir J 2006; 28: Suppl. 50, 70s Year: 2006
Comparison of two methods for estimating the predicted postoperative (PPO) lung function after lung cancer resection in COPD patients Source: Annual Congress 2009 - Preoperative functional assessment and surgery for malignant diseases Year: 2009
Accuracy of the calculated estimated postoperative pulmonary function (CEPPF) in lung cancer patients Source: Annual Congress 2007 - Prognosis and diagnosis of thoracic malignancies Year: 2007
Quantitative RT-PCR 3-gene expression signature predicts survival in early-stage non-small cell lung cancer (NSCLC) patients (pts) Source: Annual Congress 2008 - Novel trends in functional genomics and molecular pathology of neoplastic and non-neoplastic lung diseases Year: 2008
Efficacy of a pulmonary rehabilitation programme (PRP) after lung resection (LR) for cancer Source: Annual Congress 2005 - Pulmonary rehabilitation: an evidence-based intervention Year: 2005
Utility of 18 FDG-PET scan in stage 1a non small cell lung cancer (NSCLC) Source: Annual Congress 2009 - Epidemiology and management of lung cancer Year: 2009
Biological factors predicting response to chemotherapy (CT) in advanced non small cell lung cancer (NSCLC): A feasibility study on the collection of tissue Source: Annual Congress 2010 - The role of biomarkers in lung cancer Year: 2010
Is it possible to predict response to cancer chemotherapy (CTh) in patients (pts) with non-small cell lung cancer (NSCLC) on the basis of serum CYFRA 21-1 level (sCY21)? Source: Eur Respir J 2002; 20: Suppl. 38, 74s Year: 2002
Stage IIIA-N2 non-small cell lung cancer (NSCLC): comparison of prognostic factors in 257 patients treated with surgery (S) versus induction chemotherapy plus surgery (IC+S) Source: Eur Respir J 2002; 20: Suppl. 38, 597s Year: 2002
Utility of the 3-minute chair rise test (3CRT) to assess cardiopulmonary fitness of patients with non-small cell lung cancer before lung resection. Source: Virtual Congress 2020 – Thoracic surgery: developments in diagnostics and outcomes Year: 2020
Could ¹⁸F-FDG PET repeated within cycle 1 predicts objective response to chemotherapy in advanced non-small cell lung cancer (NSCLC)? A pilot study results Source: Annual Congress 2008 - Biology and diagnosis of thoracic tumours Year: 2008
A multicenter phase II study of docetaxel (D) weekly in advanced non-small cell lung cancer (NSCLC) in elderly and/or poor performance status (PS) patients (pts): preliminary results of the 0202 GFPC study Source: Annual Congress 2005 - Chemotherapy and palliative care Year: 2005
Prediction of postoperative DLCO in lung cancer patients after lobectomy. Comparison between quantitative CT and the anatomic method Source: International Congress 2016 – Surgical strategy for complex diseases Year: 2016
The effect on disease free survival of different regimens of chemotherapy (CT) in non small cell lung cancer (NSCLC) Source: Eur Respir J 2004; 24: Suppl. 48, 672s Year: 2004
How to predict fatal pneumonitis in non-small cell lung cancer (NSCLC) patients treated with radiotherapy (RT) Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018
Validation of the prognostic value of growth pattern classification in operated non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Actual challenges in thoracic surgery Year: 2010
Single institution experience in advanced non-small cell lung cancer (NSCLC) patients (pts) with erlotinib (Tarceva®) within a large extended access programme* (EAP) Source: Eur Respir J 2006; 28: Suppl. 50, 772s Year: 2006
Extrathoracic 18-FDG-PET uptakes in non small cell lung cancer (NSCLC) preoperative staging Source: Eur Respir J 2007; 30: Suppl. 51, 430s Year: 2007
Systematic review of the effect of chemotherapy on quality of life (QoL) and symptom control in patients with non-small cell lung cancer (NSCLC) Source: Annual Congress 2006 - Lung cancer treatment Year: 2006
Efficacy of next treatment received after Nivolumab (Nivo) progression in patients (pts) with non-small-cell lung cancer (NSCLC). Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies Year: 2017